Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Bayer, OrigiMed Form Companion Diagnostic Development Alliance

Bayer, OrigiMed Form Companion Diagnostic Development Alliance

Apr 30, 2020
|
staff reporter

NEW YORK — Bayer has partnered with OrigiMed on the development of a next-generation sequencing-based companion diagnostic for the cancer drug larotrectinib (Vitrakvi) for the Chinese market, the companies said on Wednesday.

Larotrectinib is a tropomyosin receptor kinase inhibitor approved in the US and Europe for the treatment of solid tumors with neurotrophic receptor tyrosine kinase (NTRK) gene fusions. Bayer acquired the exclusive rights to the drug from Loxo Oncology, now an Eli Lilly subsidiary,  last year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Millions of Tests

The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.

Court Pick and Science

Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.

Arthur Ashkin Dies

Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.

PNAS Papers on Alzheimer's Transcriptomes, Bladder Cancer Mutations, CRC Drivers

In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

What's Popular?

In Molecular Diagnostics

  1. Fluidigm Finalizes $34M NIH Contract for SARS-CoV-2 Assay Production

  2. Angle Files De Novo FDA Submission for CTC Collection Device in Breast Cancer

  3. FDA Reissues Emergency Use Authorization for Hologic SARS-CoV-2 Assay for Asymptomatic Testing

  4. Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

  5. Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.